The Annual General Meeting (the ”AGM”) on April 28, 2020 decided to adopt the balance sheet, income statement, consolidated income statement and consolidated balance sheet for 2019. Furthermore, it was resolved that no dividend will be distributed and disposable profits as of 2019-12-31 are carried forward to future periods.
The AGM also decided to discharge the board members and the CEO from liability for 2019.
The AGM approved the nominating committee’s proposal that the board shall consist of six board members.
The AGM resolved that the total board remuneration shall amount to SEK 1,946,000 whereof the remuneration to the chairman of the board shall amount to SEK 540,000 and that the remuneration to the other board members not employed by the company shall be SEK 240,000 each. For elected not employed board members living in the US an additional remuneration of SEK 96,000 is paid. The remuneration to the chairmen in the audit and remuneration committees is SEK 100,000 each and SEK 50,000 each to the other members in the committees. The AGM also decided that the remuneration to the auditor, as previous, will be on specified current account.
The AGM decided that the board until the end of the next AGM meeting will consist of the members Anders P. Wiklund, Kleanthis G. Xanthopoulos, Marios Fotiadis, Anita Tollstadius, Eva Nilsagård and Catherine Gilmore-Lawless. Anders P. Wiklund was re-elected chairman of the board. KPMG AB was re-elected as the company’s auditor, with Duane Swanson as auditor in charge, until the end of the AGM of 2021.
The AGM approved the board’s proposed remuneration guidelines for senior management.
The AGM approved the board’s proposal regarding a long-term incentive program 2020 (LTIP 2020) in accordance with items A and B of the proposal.
The AGM approved the board’s proposal for a resolution authorizing the board to resolve to issue warrants to secure delivery of shares to participants in the company’s outstanding incentive program, in addition to LTIP 2020, and to cover any upcoming social contributions due to the programs.
The AGM confirmed that the term of the options in incentive program 1 shall be up to and including 30 September 2025.
The AGM approved the board’s proposal to be authorized to increase share capital through the issue of new shares and/or convertibles.
Complete proposals regarding the AGM’s decisions are available on IRRAS AB:s website www.irras.com.
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq First North Premier Growth Market (ticker: IRRAS). Redeye AB is certified adviser of the company with email, email@example.com, or phone +46 8 121 576 90.
For more information, please contact:
+46 73 951 95 02
The information was released for public disclosure, through the agency of the contact person above, on April 28, 2020 at 19:00 (CET).